Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02290951 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | PHASE1 | COMPLETED | 200 | — | — | Jan 9, 2015 | Aug 21, 2025 | Oct 10, 2025 | 22 | United States, France +3 |
Part A and B
Part A and B
Expansion Cohorts: • Diffuse large B-cell lymphoma (DLBCL) after failure of CAR-T therapy Part A
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | DLBCL post CAR-T |
| 1N Part B | EXPERIMENTAL | FL |
| 2N Part B | EXPERIMENTAL | DLBCL |
| Name | Type | Description |
|---|---|---|
| Odronextamab multiple dose levels | DRUG | Administered by intravenous (IV) infusion |
Key Inclusion Criteria: 1. Have documented CD20+ B-cell malignancy, with active disease not responsive to prior therapy, for whom no standard of care options exists, and for whom treatment with an anti-CD20 antibody may be appropriate: * Part A (IV administration) B-NHL confirmed by National Ca...